BAYN.DE Bayer AG N
Healthcare · Drug Manufacturers - General
49.04
+0.76%
About the company
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment offers nonprescription over-the-counter medicines for self-medication and self-care; nutritional supplements; allergy, cough, and cold; dermatology; pain and cardiovascular risk prevention; and digestive health products. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solutions, and pest and weed management products, as well as customer services for agriculture. It also engages in the breeding, propagation, and production/processing of seeds, including seed dressing. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft has a Strategic Alliance with The University of Colorado Anschutz, along with UCHealth and Children's Hospital Colorado to advance drug development and clinical trials. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.
52-week range
Dividend deep dive
Bayer AG (BAYN.DE), a Healthcare sector Drug Manufacturer, shows a current dividend yield of 0.23%. This is significantly below its 5-year average yield of 2.71% and its 5-year high of 5.13%, indicating an "overvalued" status by Yield Theory. The company has a low rating score of 1.0. It exhibits strong price momentum with a score of 10.0, but a poor value score of 0.0, suggesting it is currently expensive relative to intrinsic value.
Dividend history
Bayer AG has a dividend increase streak of 0 years, reflecting inconsistent dividend payments. The 3-year dividend CAGR is -0.6197%, and the 5-year dividend CAGR is -0.4766%, indicating negative growth over these periods. Recent annual dividends include EUR 2.8 in 2019 and 2020, EUR 2.0 in 2021 and 2022, EUR 2.4 in 2023, and a projected EUR 0.11 for 2024 and 2025. This demonstrates a pattern of decreasing dividends in recent years.
Dividend safety
The dividend safety status for Bayer AG is "at_risk." The company has a high debt-to-equity ratio of 134.269%. Liquidity metrics show a current ratio of 1.055 and a quick ratio of 0.695. The payout ratio is not available.
Quantic · Free
Read the rest of the safety verdict
Plus the key risks and what to watch next — free, no card.
AI-generated from Quantic's dividend data · Updated 24 Aug 2026 · Information, not financial advice.
Price history
Dividend profile
Yield band A stock's current dividend yield shown against its own range over the past five years — the low, average and high. Near the high end the shares look relatively cheap for the income they pay; near the low end, relatively expensive. It's the picture behind Dividend Yield Theory. Learn more → (5-year)
Payment calendar
Dividend history
Per-share dividend by year
Debt & leverage
Latest reported balance-sheet figures.
Held by 1 investor · watched by 1
Appears in these lists
BAYN.DE qualifies for these curated dividend rankings.
New to dividend investing?
Information, not financial advice.
Quantic · Free
Track BAYN.DE and your whole portfolio
Real yield, dividend safety, net-of-tax income and your path to freedom — free, no broker connection.
Need more? Pro adds portfolios, options income tracking & more AI. See Pro →